Related Experiment Video
Updated: Apr 10, 2026

Production of Human CRISPR-Engineered CAR-T Cells
Published on: March 15, 2021
CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies--Immuno-oncology
Dominik Wolf1, Anna Maria Wolf1
1Medical Clinic III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn (UKB), Bonn, Germany. Laboratory of Tumor Immunology, Department of Medicine V, Medical University Innsbruck, Innsbruck, Austria. dominik.wolf@ukb.uni-bonn.de anna_maria.wolf@ukb.uni-bonn.de.
Abstract:
Immune escape is a hallmark of cancer development and metastasis. Regulatory T cells (Treg) are potent inhibitors of cancer immune surveillance but also prevent inflammation-driven tumorigenesis. The study by Wolf and colleagues, which was published in the February 2003 issue of Clinical Cancer Research, showed the expansion of Treg in solid cancer patients, providing a deeper understanding of cancer immune escape mechanisms that later set the stage for the development of scientific breakthroughs in cancer immunotherapy.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Treatment Resistent Cancers
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Treatment Resistant Cancers

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)